Login / Signup

Characteristics associated with significantly worse quality of life in mycosis fungoides/Sézary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study.

Kevin MolloyC JonakF J S H Woei-A-JinE GuenovaA M BusschotsA BervoetsE HaubenR KnoblerS PorkertC FassnachtR CowanE PapadavidMarie Beylot-BarryE BertiS Alberti ViolettiT EstrachR MatinOleg E AkilovL VakevaM PrinceA BatesM BayneR WachsmuchU WehkampM MarschalkoO ServitjeD TurnerS WeatherheadM WobserJ A SanchesP McKayD KlemkeC PengA HowlesJ YooF EvisonJ Scarisbrick
Published in: The British journal of dermatology (2019)
HRQoL is significantly more impaired in newly diagnosed women with MF/SS and in those with alopecia. As Skindex-29 does not include existential questions on cancer, which may cause additional worry and distress, a comprehensive validated cutaneous T-cell lymphoma-specific questionnaire is urgently needed to more accurately assess disease-specific HRQoL in these patients. What's already known about this topic? Cross-sectional studies of mixed populations of known and newly diagnosed patients with mycosis fungoides (MF)/Sézary syndrome (SS) have shown significant impairment in health-related quality of life (HRQoL). Previous studies on assessing gender-specific differences in HRQoL in MF/SS are conflicting. More advanced-stage disease and pruritus is associated with poorer HRQoL in patients with MF/SS. What does this study add? This is the first prospective study to investigate HRQoL in a homogenous group of newly diagnosed patients with MF/SS. In patients newly diagnosed with MF/SS, HRQoL is worse in women and in those with alopecia and confluent erythema. MF/SS diagnosis has a multidimensional impact on patient HRQoL, including a large burden of cutaneous symptoms, as well as a negative impact on emotional well-being.
Keyphrases